Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...

Shares of Pyxis Oncology (NASDAQ:PYXS) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at head and ...

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average recommendation of “Moderate Buy” from ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients.

The completion of the $3.0 million common share repurchase program demonstrates Pyxis Tankers' commitment to returning value to shareholders and potentially enhancing share price. Redemption of ...

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges.

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeuti BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE ...